Flipping a Gene Switch Reactivates Fetal Hemoglobin, May Reverse Sickle Cell Disease
In Lab Studies, CHOP Researchers Reprogram Gene Expression, Showing Proof-of-Concept fro Potential Therapy
Embargo expired: 12/8/2013 12:05 PM EST
Source Newsroom: Children's Hospital of Philadelphia
EMBARGOED FOR RELEASE
Until Sunday, Dec. 8, 2013, noon ET (11 a.m. CT)
Newswise — Philadelphia and New Orleans, Dec. 8, 2013 – Hematology researchers at The Children’s Hospital of Philadelphia have manipulated key biological events in adult blood cells to produce a form of hemoglobin normally absent after the newborn period. Because this fetal hemoglobin is unaffected by the genetic defect in sickle cell disease (SCD), the cell culture findings may open the door to a new therapy for the debilitating blood disorder.
“Our study shows the power of a technique called forced chromatin looping in reprogramming gene expression in blood-forming cells,” said hematology researcher Jeremy W. Rupon, M.D., Ph.D., of The Children’s Hospital of Philadelphia. “If we can translate this approach to humans, we may enable new treatment options for patients.”
Rupon presented the team’s findings today at a press conference during the annual meeting of the American Society of Hematology (ASH) in New Orleans. Rupon worked in collaboration with a former postdoctoral fellow, Wulan Deng, Ph.D., in the laboratory of Gerd Blobel, M.D., Ph.D.
Hematologists have long sought to reactivate fetal hemoglobin as a treatment for children and adults with SCD, the painful, sometimes life-threatening genetic disorder that deforms red blood cells and disrupts normal circulation.
In the normal course of development, a biological switch flips during the production of hemoglobin, the oxygen-carrying component of red blood cells. Regulatory elements in DNA shift the body from producing the fetal form of hemoglobin to producing the adult form instead. This transition occurs shortly after birth. When patients with SCD undergo this transition, their inherited gene mutation distorts adult hemoglobin, forcing red blood cells to assume a sickled shape.
In the current study, Rupon and Blobel reprogrammed gene expression to reverse the biological switch, causing cells to resume producing fetal hemoglobin, which is not affected by the SCD mutation, and produces normally shaped red blood cells.
The scientists built on previous work by Blobel’s team showing that chromatin looping, a tightly regulated interaction between widely separated DNA sequences, drives gene transcription—the conversion of DNA code into RNA messages to carry out biological processes.
In the current study, the researchers used a specialized tool, a genetically engineered zinc finger (ZF) protein, which they custom-designed to latch onto a specific DNA site carrying the code for fetal hemoglobin. They attached the ZF to another protein that forced a chromatin loop to form. The loop then activated gene expression that produced embryonic hemoglobin in blood-forming cells from adult mice. The team obtained similar results in human adult red blood cells, forcing the cells to produce fetal hemoglobin.
Rupon and Blobel will continue investigations aimed at moving their research toward clinical application. Rupon added that the approach may also prove useful in treating other diseases of hemoglobin, such as thalassemia.
Financial support for this study came from the National Institutes of Health (grants 5R37DK058044 and RO1HL119479-01) and a fellowship award from the American Heart Association. Wulan Deng, Ph.D., a former member of Blobel’s lab, is a co-author of the study. Other co-authors include scientists from Sangamo Biosciences, which designed the zinc finger proteins. In addition to his position at Children’s Hospital, Blobel is also at the Perelman School of Medicine at the University of Pennsylvania.
Note to Reporters: For interviews with Dr. Jeremy Rupon or Dr. Gerd Blobel, please contact Rachel Salis-Silverman, cell: 267-970-3685; firstname.lastname@example.org.
“Using Forced Chromatin Looping to Overcome Developmental Silencing of Embryonic and Fetal beta-Type Globin Genes in Adult Erythroid Cells”
--Abstract 59341, presented Sun., Dec. 8, 2013, 11 a.m. CT; Press Conference to occur in the ASH Press Room, Rm. 356-357, Ernest N. Morial Convention Center--
About The Children’s Hospital of Philadelphia: The Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children’s Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program receives the highest amount of National Institutes of Health funding among all U.S. children’s hospitals. In addition, its unique family-centered care and public service programs have brought the 535-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.